Modalis Therapeutics Secures Japanese Patent for Gene Therapy

MT Newswires Live01-27

Modalis Therapeutics' (TYO:4883) patent application for CRISPR-GNDM(r) based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.

LAMA2-CMD is a severe congenital muscular dystrophy caused by the absence of the LAMA2 protein, for which there are currently no effective treatments due to the gene's large size.

Modalis' CRISPR-GNDM technology offers a novel solution by increasing the expression of the LAMA1 gene to compensate for LAMA2 deficiency without introducing double-strand DNA breaks.

The patent, alongside the US orphan drug designation, strengthens Modalis' intellectual property and paves the way for securing patents in other major countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2506712375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-27 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506712375","market":"us","top_or_hot":-1,"title":"Modalis Therapeutics Secures Japanese Patent for Gene Therapy","media":"MT Newswires Live","content":"<html><body><p> Modalis <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (TYO:4883) patent application for CRISPR-GNDM(r) based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.</p><p>LAMA2-CMD is a severe congenital muscular dystrophy caused by the absence of the LAMA2 protein, for which there are currently no effective treatments due to the gene's large size.</p><p>Modalis' CRISPR-GNDM technology offers a novel solution by increasing the expression of the LAMA1 gene to compensate for LAMA2 deficiency without introducing double-strand DNA breaks.</p><p>The patent, alongside the US orphan drug designation, strengthens Modalis' intellectual property and paves the way for securing patents in other major countries.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Modalis Therapeutics Secures Japanese Patent for Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModalis Therapeutics Secures Japanese Patent for Gene Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-27 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Modalis Therapeutics' (TYO:4883) patent application for CRISPR-GNDM(r) based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.LAMA2-CMD is a severe ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2506712375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506712375","pubTimestamp":1737979101,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Modalis Therapeutics'  patent application for CRISPR-GNDM based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.LAMA2-CMD is a severe congenital muscular dystrophy caused by the absence of the LAMA2 protein, for which there are currently no effective treatments due to the gene's large size.Modalis' CRISPR-GNDM technology offers a novel solution by increasing the expression of the LAMA1 gene to compensate for LAMA2 deficiency without introducing double-strand DNA breaks.The patent, alongside the US orphan drug designation, strengthens Modalis' intellectual property and paves the way for securing patents in other major countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Modalis Therapeutics获得日本基因治疗专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CRSP":0.81},"content_text":"Modalis Therapeutics' (TYO:4883) patent application for CRISPR-GNDM(r) based gene therapy MDL-101 as a treatment for LAMA2-CMD was granted in Japan, according to a Friday filing.LAMA2-CMD is a severe congenital muscular dystrophy caused by the absence of the LAMA2 protein, for which there are currently no effective treatments due to the gene's large size.Modalis' CRISPR-GNDM technology offers a novel solution by increasing the expression of the LAMA1 gene to compensate for LAMA2 deficiency without introducing double-strand DNA breaks.The patent, alongside the US orphan drug designation, strengthens Modalis' intellectual property and paves the way for securing patents in other major countries.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2506712375"}